biostudies-literatureHamer MJNational Institute of Allergy and Infectious DiseasesIntramural NIH HHSNational Institutes of Health294-302https://www.ebi.ac.uk/biostudies/studies/S-EPMC10127441biostudies-literatureUnknown401(10373)<h4>Background</h4>WHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults.<h4>Methods</h4>We did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18-50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 10¹⁰ or 1 × 10¹¹ particle units (pu). PrimarLancet (London, England)Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.PMC10127441Z99 AI999999Hickman SMurray TSchech STrofymenko OWilson HScott PTStrom LCoates EEPloquin ACostner PGordon IJAmare MFKioko VLarkin BO'Connell SGall JGSullivan NJHamer MJMcCauley MDWidge ATLampley RDulan CNMMcDermott ABPreston ARV 507 Study TeamLedgerwood JEHouser KVBasappa MWaterman PEFlach BStanley DAAndrews CNarpala SRRead MPadilla MGaudinski MRLee CAugustine BKoup RACox JHSwanson PAHofstetter ARVazquez SAke JAStorme CHolman LAModjarrad KMascola JROrtega-Villa AMHunegnaw RRobb MLYamshchikov GVHutter JNThillainathan JMorgan PHappe MfalseSafety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.<h4>Background</h4>WHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults.<h4>Methods</h4>We did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18-50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 10¹⁰ or 1 × 10¹¹ particle units (pu). Primar2023-01-01T00:00:00Z2023 Jan2026-06-02T06:12:41.119Z2024-11-12T22:32:29.008ZS-EPMC101274413670907410.1016/S0140-6736(22)02400-X10.1016/s0140-6736(22)02400-x